CO2020001322A2 - Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante - Google Patents
Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinanteInfo
- Publication number
- CO2020001322A2 CO2020001322A2 CONC2020/0001322A CO2020001322A CO2020001322A2 CO 2020001322 A2 CO2020001322 A2 CO 2020001322A2 CO 2020001322 A CO2020001322 A CO 2020001322A CO 2020001322 A2 CO2020001322 A2 CO 2020001322A2
- Authority
- CO
- Colombia
- Prior art keywords
- von willebrand
- patients
- administration
- treatment
- gastrointestinal bleeding
- Prior art date
Links
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 title abstract 2
- 208000027276 Von Willebrand disease Diseases 0.000 title abstract 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 title abstract 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530027P | 2017-07-07 | 2017-07-07 | |
| PCT/US2018/041320 WO2019010497A1 (en) | 2017-07-07 | 2018-07-09 | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020001322A2 true CO2020001322A2 (es) | 2020-02-18 |
Family
ID=63036433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0001322A CO2020001322A2 (es) | 2017-07-07 | 2020-02-06 | Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10632176B2 (https=) |
| EP (2) | EP3648788B1 (https=) |
| JP (2) | JP7307047B2 (https=) |
| KR (2) | KR20260037107A (https=) |
| CN (1) | CN111436193A (https=) |
| AU (2) | AU2018298233B2 (https=) |
| BR (1) | BR112020000321A2 (https=) |
| CA (1) | CA3069295A1 (https=) |
| CO (1) | CO2020001322A2 (https=) |
| DK (1) | DK3648788T3 (https=) |
| ES (1) | ES2986574T3 (https=) |
| FI (1) | FI3648788T5 (https=) |
| MX (1) | MX2025012580A (https=) |
| PL (1) | PL3648788T3 (https=) |
| PT (1) | PT3648788T (https=) |
| WO (1) | WO2019010497A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3069295A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
| US20220395560A1 (en) * | 2019-02-01 | 2022-12-15 | Takeda Pharmaceutical Company Limited | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) |
| US12128090B2 (en) * | 2019-02-01 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Methods of prophylactic treatment using recombinant VWF (rVWF) |
| EP4013389A1 (en) * | 2019-08-16 | 2022-06-22 | Octapharma AG | Stabilizing buffer for factor viii and vwf |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| JPS62502589A (ja) | 1985-04-11 | 1987-10-08 | ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン | フオン・ビルブラント因子 |
| US8597910B1 (en) | 1985-04-11 | 2013-12-03 | Children's Medical Center Corporation | DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US6005077A (en) | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CA2591852A1 (en) | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| EP3653699A1 (en) | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
| ES2392569T3 (es) | 2007-06-13 | 2012-12-11 | Csl Behring Gmbh | Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias |
| CA2704234A1 (en) | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| CN105816858B (zh) | 2007-12-28 | 2024-10-18 | 武田药品工业株式会社 | 重组vwf配方 |
| KR101648734B1 (ko) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| EP2349314B1 (en) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| AU2010279463A1 (en) | 2009-08-04 | 2012-03-01 | Baxter Healthcare S.A. | Transgenic mouse knockout for FVIII and VWF - model of hemophilia A |
| CA2805557A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | Method of producing recombinant high molecular weight vwf in cell culture |
| ES2682249T3 (es) * | 2011-06-10 | 2018-09-19 | Baxalta GmbH | Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante |
| ES2772933T3 (es) | 2015-03-06 | 2020-07-08 | CSL Behring Lengnau AG | Factor de von Willebrand modificado que tiene una semivida mejorada |
| CA3069295A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
-
2018
- 2018-07-09 CA CA3069295A patent/CA3069295A1/en active Pending
- 2018-07-09 CN CN201880057599.9A patent/CN111436193A/zh active Pending
- 2018-07-09 EP EP18746458.1A patent/EP3648788B1/en active Active
- 2018-07-09 JP JP2020500617A patent/JP7307047B2/ja active Active
- 2018-07-09 BR BR112020000321-2A patent/BR112020000321A2/pt unknown
- 2018-07-09 PT PT187464581T patent/PT3648788T/pt unknown
- 2018-07-09 KR KR1020267002897A patent/KR20260037107A/ko active Pending
- 2018-07-09 EP EP24176324.2A patent/EP4424366A3/en active Pending
- 2018-07-09 PL PL18746458.1T patent/PL3648788T3/pl unknown
- 2018-07-09 WO PCT/US2018/041320 patent/WO2019010497A1/en not_active Ceased
- 2018-07-09 FI FIEP18746458.1T patent/FI3648788T5/fi active
- 2018-07-09 DK DK18746458.1T patent/DK3648788T3/da active
- 2018-07-09 AU AU2018298233A patent/AU2018298233B2/en active Active
- 2018-07-09 ES ES18746458T patent/ES2986574T3/es active Active
- 2018-07-09 US US16/030,659 patent/US10632176B2/en active Active
- 2018-07-09 KR KR1020207003264A patent/KR102921337B1/ko active Active
-
2020
- 2020-01-08 MX MX2025012580A patent/MX2025012580A/es unknown
- 2020-02-06 CO CONC2020/0001322A patent/CO2020001322A2/es unknown
- 2020-02-26 US US16/802,118 patent/US10905746B2/en active Active
- 2020-12-01 US US17/108,562 patent/US11529395B2/en active Active
-
2022
- 2022-12-06 US US18/062,534 patent/US12016904B2/en active Active
-
2023
- 2023-06-29 JP JP2023106554A patent/JP7641327B2/ja active Active
-
2024
- 2024-06-12 US US18/741,650 patent/US20240316160A1/en active Pending
-
2025
- 2025-07-11 AU AU2025205392A patent/AU2025205392A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001322A2 (es) | Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante | |
| CL2022002836A1 (es) | Polipeptidos derivados de cancer (divisional 201902533) | |
| CO2019001044A2 (es) | Composición de cannabis | |
| CL2019000266A1 (es) | Composición de cannabis. | |
| AR086904A1 (es) | Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf) | |
| PE20191345A1 (es) | Administracion viral de neoantigenos | |
| MX2020008017A (es) | Formulaciones de vidrio y usos de las mismas. | |
| EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| MX2022005664A (es) | Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer. | |
| CO2020001314A2 (es) | Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante | |
| CO2021011340A2 (es) | Métodos de tratamiento profiláctico con vwf recombinante (rvwf) | |
| EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением | |
| MX2022005448A (es) | Método de tratamiento de queratodermia palmoplantar. | |
| MX382676B (es) | Una composición que incluye por lo menos un antagonista gnrh. | |
| MX383214B (es) | COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO. | |
| PE20211376A1 (es) | Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham | |
| CL2017003143A1 (es) | Composición multi-péptido. | |
| AR118608A2 (es) | TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE | |
| MX2018010367A (es) | Titulacion de cebranopadol. | |
| MX2022009492A (es) | Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante. | |
| AR118192A1 (es) | ADMINISTRACIÓN DE b-SARCOGLICANO CON UN VECTOR DE VIRUS ADENOASOCIADO Y TRATAMIENTO DE LA DISTROFIA MUSCULAR | |
| CY1124859T1 (el) | Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων |